• Diabetes


Indications for FIASP:



Individualize. SC inj: give at start of meal or within 20mins after starting meal. Rotate inj sites (abdomen, upper arm, thigh). Use with intermediate or long-acting insulin. CSII: see full labeling. IV infusion: give under medical supervision with close monitoring (see full labeling). Switching from other insulins: convert on a unit-to-unit basis (see full labeling). Onset approx. 2.5mins, peak approx. 1.5–2hrs, duration approx. 5–7hrs.


Not established.


During episodes of hypoglycemia.


Do not share pens, PenFills between patients, or needles and syringes when using vials. Instruct patients on proper administration of insulin, check insulin label before each injection, and management of hypoglycemia. Increased risk of hypo- or hyperglycemia if changes in physical activity, meal patterns, concomitant medications, renal or hepatic function, insulin regimen and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Monitor potassium levels in patients at risk for hypokalemia (eg, concomitant K+-lowering or K+-sensitive drugs). Discontinue if hypersensitivity reactions occur. Possible hyperglycemia and ketoacidosis due to insulin pump device malfunction; have alternate insulin therapy available. Renal or hepatic impairment. Elderly. Pregnancy. Nursing mothers.


Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by antidiabetic agents, ACE inhibitors, ARBs, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, salicylates, somatostatin analogs (eg, octreotide), sulfonamide antibiotics. Antagonized by atypical antipsychotics, corticosteroids, isoniazid, niacin, danazol, diuretics, glucagon, phenothiazines, sympathomimetics, somatropin, thyroid hormones, oral contraceptives, estrogens, progestogens, protease inhibitors. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. Concomitant β-blockers, clonidine, guanethidine, reserpine may blunt hypoglycemia.

Adverse Reactions:

Hypoglycemia, allergic reactions, hypersensitivity, inj site reactions, lipodystrophy, weight gain, hypokalemia, peripheral edema.

Generic Availability:


How Supplied:

Vials (10mL)—1; FlexTouch (3mL prefilled pen)—1; PenFill (3mL cartridges)—5

Pricing for FIASP

10ml of 100 units/ml vial (Qty: 3)
Appx. price $868